Ronald Levy, MD

Clinical Focus

• Cancer> Lymphoma
• Lymphoma
• Non-Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma - Medical Oncology
• Burkitt's Lymphoma

Honors and Awards

• King Faisal International Prize, King Faisal Foundation (2009)
• Member, National Academy of Sciences (2008)
• di Villiers International Achievement Award, Leukemia and Lymphoma Society (2007)
• Member, Institute of Medicine (2007)
• Damashek Prize, American Society of Hematology (2004)

Professional Education

Postdoctoral Advisees

Stacey Adam,  MIchael Green,  Yulin Li,  Aurelien Marabelle

Internet Links

• http://med.stanford.edu/labs/ronald_levy/
• Personal Web site

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

Our research concentrates on the study of malignant lymphoma and tumors of the immune system using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Receptor molecules present on the surface of tumor cells transmit signals for regulation of cell growth. These receptors include the immunoglobulin molecule on B cell tumors and the T cell receptor on T cell tumors. Questions the lab is currently addressing include:
1. Can a clue to the pathogenesis of lymphoma be derived from a study of their antigen receptors?
2. Can new treatments for lymphoma be developed by targeting receptors with monoclonal antibodies?
3. Can vaccines be developed which can induce an immune response in the host against the receptors on their own tumor?

Clinical Trials

• A Phase 1 Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Recruiting
• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease Recruiting
• Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy Recruiting
• Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
• Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of BMS-663513 in Subjects With Advanced and/or Metastatic Solid Tumors Recruiting

Publications

• Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137 Expressing Regulatory T Cells. Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, Levy R. Cancer Res. 2012
• Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. Sagi Y, Landrigan A, Levy R, Levy S. Proc Natl Acad Sci U S A. 2012; 109 (5): 1613-8
• A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R. Blood. 2011; 117 (1): 118-27
• Active and passive immunotherapy for lymphoma: proving principles and improving results. Brody J, Kohrt H, Marabelle A, Levy R. J Clin Oncol. 2011; 29 (14): 1864-75
• CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. Blood. 2011; 117 (8): 2423-32